2026-01-11 - Analysis Report
# ğŸ“Š Meta Platforms Inc. â€“ 2026 Market Snapshot

> **Quick glance** â€“ All figures are current as of 2026â€‘01â€‘10.

---

## 1ï¸âƒ£ Return Comparison vs. S&Pâ€¯500 (VOO)

| Item | Value |
|------|-------|
| **META cumulative return** | **106.1â€¯%** |
| **VOO cumulative return** | 94.0â€¯% |
| **Absolute divergence** | **+12.1â€¯%** |
| **Relative divergence** | **52.8â€¯%** (midâ€‘range) |

**Interpretation**  
- META has outperformed VOO by ~12â€¯% on the cumulative basis.  
- Its relative divergence of 52.8â€¯% places it in the median of historical performance spreads (not a â€œsuperâ€‘returnâ€ but solid).

---

## 2ï¸âƒ£ Company Snapshot

- **Meta Platforms Inc.** â€“ Global leader in social networking, virtual reality, and AIâ€‘driven commerce platforms.

---

## 3ï¸âƒ£ Alphaâ€‘Beta & Capital Performance (2016â€‘2025)

| Period | CAGR | MDD | Alpha | Beta | Capital (B$) |
|--------|------|-----|-------|------|--------------|
| 2016â€‘18 | â€‘17â€¯% | 38.5â€¯% | â€‘21â€¯% | 1.2 | 330.4 |
| 2017â€‘19 | 10â€¯% | 38.5â€¯% | â€‘7â€¯% | 1.3 | 517.3 |
| 2018â€‘20 | 0â€¯% | 38.5â€¯% | â€‘20â€¯% | 1.1 | 688.5 |
| 2019â€‘21 | 35â€¯% | 20.9â€¯% | â€‘8â€¯% | 1.1 | 847.8 |
| 2020â€‘22 | â€‘54â€¯% | 65.8â€¯% | â€‘52â€¯% | 1.2 | 303.3 |
| 2021â€‘23 | 16â€¯% | 65.8â€¯% | 15â€¯% | 1.7 | 892.2 |
| 2022â€‘24 | 69â€¯% | 61.3â€¯% | 49â€¯% | 1.7 | 1,475.8 |
| 2023â€‘25 | 132â€¯% | 27â€¯% | 70â€¯% | 1.5 | 1,663.8 |

**Key takeâ€‘aways**

- **Alpha** swung from negative (â€‘21â€¯%) to positive (+70â€¯%) over the last two years, reflecting a strong turnaround.  
- **Beta** consistently above 1 â†’ higher systematic risk; 1.5â€‘1.7 in the most recent periods.  
- **MDD** peaked in 2020â€‘22 but has since fallen to 27â€¯% (2023â€‘25).  
- Capital base has more than tripled, underscoring massive scale growth.

---

## 4ï¸âƒ£ Recent Price Dynamics

- **Close**: 653.06â€¯$  
- **Lastâ€‘market**: +1.08â€¯$ (1.07â€¯% up from 646.06â€¯$)  
- **5â€‘day SMA**: 653.44â€¯$ â†’ price just below SMA  
- **20â€‘day SMA**: 656.70â€¯$ â†’ price below 20â€‘day trend  
- **60â€‘day SMA**: 658.17â€¯$ â†’ price still below the longerâ€‘term trend  

**Bottom line** â€“ Shortâ€‘term trend is slightly bearish; momentum may need support to break above the 20â€‘/60â€‘day SMAs.

---

## 5ï¸âƒ£ Technical Indicators & Risk Snapshot

| Indicator | Value | Comment |
|-----------|-------|---------|
| MRI (Market Risk) | 0.70 | **Medium** â€“ moderate risk, not a â€œhighâ€‘returnâ€ zone |
| RSI | 42.7 | Neutral, not overbought/oversold |
| PPO | â€‘0.21 | Negative trend in price momentum |
| Î”â€¯Prev. Rel. Divergence | â€‘1.3 | Slight worsening trend |
| 7â€‘Day Rank | â€‘1 | Small drop in ranking |
| 7â€‘Day Dynamic Expected Return | +1.0 | Improving shortâ€‘term outlook |
| **Expected Return** (â‰¥2â€‘yr) | **7.8â€¯%** | Exceeds S&Pâ€¯500 by ~3â€¯% (approx.) |

**Hybrid Signal** â€“ â€œBuy 90â€¯% of cash (1â€¯share, safe, MRIâ€¯0.80) â€“ Monthly invest 0.8â€¯% of total (1â€¯000â€¯$).â€  
- Indicates a **cautionary but opportunistic** stance.

---

## 6ï¸âƒ£ Headlines & Events (Janâ€¯2026)

| Date | Source | Summary |
|------|--------|---------|
| 2026â€‘01â€‘09 | Benzinga | Meta clinches Mega Nuclear deal â†’ sharp jump |
| 2026â€‘01â€‘09 | The Motley Fool | Meta flagged as â€œBuyâ€ for 2026 â€“ bullish tone |
| 2026â€‘01â€‘08 | Seeking Alpha | China review adds uncertainty â†’ slight dip |
| 2026â€‘01â€‘09 | Yahoo Finance | Jimâ€¯Cramer endorses Meta as â€œPositive for holdersâ€ |
| 2026â€‘01â€‘10 | MarketBeat | Penobscot lifts stake â€“ institutional confidence |
| 2026â€‘01â€‘08 | Investor's Business Daily | AI acquisition faces China scrutiny â€“ potential regulatory risk |

**Takeaway** â€“ Mixed news: strong growth announcements offset by regulatory headwinds; overall sentiment remains bullish.

---

## 7ï¸âƒ£ Analyst Consensus

- **Rating**: **Strongâ€¯Buy** (Meanâ€¯=â€¯1.36, 59 analysts)  
- **Targets**: Avgâ€¯=â€¯835.54â€¯$; Highâ€¯=â€¯1,117.00â€¯$; Lowâ€¯=â€¯685.00â€¯$  
- **Recent Rating Changes**: No significant moves in the latest cycle.  

**Bottom line** â€“ Market consensus strongly favors Meta, with optimistic price targets.

---

## 8ï¸âƒ£ Earnings History (Qâ€‘4 FY 2025)

| Date | EPS (USD) | Revenue (B$) |
|------|----------|--------------|
| 2025â€‘10â€‘30 | 1.08 | 51.24 |
| 2025â€‘07â€‘31 | 7.28 | 47.52 |
| 2025â€‘05â€‘01 | 6.59 | 42.31 |
| 2024â€‘10â€‘31 | 6.20 | 40.59 |
| 2025â€‘10â€‘30 | 6.20 | 40.59 |

**Analysis**

- **EPS growth** is robust, especially Q3 (7.28â€¯$) and Q4 (1.08â€¯$ â€“ a dip but still solid).  
- **Revenue** climbed steadily from 40.59â€¯B$ to 51.24â€¯B$ (+25â€¯%) over the period.  
- Quarterly **margin** remains high (~82â€¯%), reflecting efficient cost structure.

---

## 9ï¸âƒ£ Revenue & Profitability (2024â€‘2025 Qâ€‘3)

| Quarter | Revenue (B$) | Profit Margin |
|---------|--------------|---------------|
| 2025â€‘09â€‘30 | 51.24 | 82.03â€¯% |
| 2025â€‘06â€‘30 | 47.52 | 82.13â€¯% |
| 2025â€‘03â€‘31 | 42.31 | 82.11â€¯% |
| 2024â€‘12â€‘31 | 48.38 | 81.73â€¯% |
| 2024â€‘09â€‘30 | 40.59 | 81.83â€¯% |

**Insight** â€“ Margins are consistently in the 82â€¯% range; revenue growth is steady, indicating healthy scaling.

---

## ğŸ”Ÿ Capital & ROE (2024â€‘2025 Qâ€‘3)

| Quarter | Equity (B$) | ROE |
|---------|-------------|-----|
| 2025â€‘09â€‘30 | 194.07 | 1.40â€¯% |
| 2025â€‘06â€‘30 | 195.07 | 9.40â€¯% |
| 2025â€‘03â€‘31 | 185.03 | 9.00â€¯% |
| 2024â€‘12â€‘31 | 182.64 | 11.41â€¯% |
| 2024â€‘09â€‘30 | 164.53 | 9.54â€¯% |

**Observations**

- **Equity** is expanding, but ROE dipped sharply in Q3 2025 (~1.4â€¯%) due to higher leverage or lower earnings.  
- Historical ROE (~9â€“11â€¯%) is moderate; investors should monitor profitability trends.

---

## ğŸ“Œ Comprehensive Summary

- **Outperformance**: METAâ€™s cumulative return surpasses VOO by ~12â€¯%; medium relative divergence suggests solid but not extreme performance.  
- **Risk profile**: Medium MRI, neutral RSI, negative PPO, high beta â†’ systematic risk remains high but manageable.  
- **Momentum**: Shortâ€‘term SMAs are below current price; price needs to test 20â€‘/60â€‘day SMAs to confirm trend reversal.  
- **Fundamental health**: Strong revenue growth, high margins, but ROE variance warrants attention.  
- **Sentiment**: Strong analyst consensus, bullish news, institutional stake increases.  
- **Earnings**: Consistent EPS and revenue growth with stable high margins.  

**Recommendation** â€“ For a mediumâ€‘risk appetite, Meta remains a **Strongâ€¯Buy** with a target range of 685â€“1,117â€¯$ and an expected longâ€‘term return of 7.8â€¯%. Monitor regulatory developments (China) and momentum signals (SMAs, PPO) for shortâ€‘term trade decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.